Safety, efficacy, and PKPD of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with advanced neuroendocrine cancers: Results from a multi-center multi-country phase 1/2a expansion cohort.

23ME-00610 - 23andMe

https://meetings.asco.org/abstracts-presentations/234312/

Drew W. Rasco; Albiruni Ryan Abdul Razak; Ali Raza Khaki; Alexander I. Spira; Ching-Chang Hwang; Anh N. Diep; Maike Schmidt; Roo Vold; Sophia Majeed; Dylan M. Glatt

Apr 25, 2024